Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Pemvidutide improves liver fat and body weight in MASLD
Última actualización 22 de julio de 2026
Key finding
Pemvidutide achieved a relative reduction in liver fat content of 56.3% from baseline.
This study evaluated the effects of pemvidutide on liver fat content in individuals with metabolic dysfunction-associated steatotic liver disease over 24 weeks.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of pemvidutide on liver fat content in individuals with metabolic dysfunction-associated steatotic liver disease over 24 weeks.
Clinical relevance
These findings highlight the potential of pemvidutide as a therapeutic option for individuals suffering from metabolic dysfunction-associated steatotic liver disease, a condition that can lead to serious liver complications. Reducing liver fat is crucial for improving overall liver health and preventing further metabolic issues.
Keep in mind
Limited sample size may affect generalizability. Short duration of 24 weeks may not capture long-term effects. No significant difference in body weight reduction compared to placebo.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Sarah KB, John JS, Shaheen T, et al. Pemvidutide Treatment in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease: A 24-Week Extension Study. JHEP Reports. 2025;7(11):101483. doi:10.1016/j.jhepr.2025.101483
Efectos Principales
Pemvidutide 1.2 mg achieved a 56.3% reduction in liver fat content.
Pemvidutide 1.8 mg achieved a 75.2% reduction in liver fat content.
Pemvidutide 2.4 mg achieved a 76.4% reduction in liver fat content.
Body weight was reduced by 6.2% over 24 weeks of treatment.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Pemvidutide 1.2 mg, Pemvidutide 1.8 mg, Pemvidutide 2.4 mg and Body weight, Liver fat content.
This study contributes evidence to
Primary intervention
Pemvidutide 1.2 mg
Primary outcomes
- Body weight
- Liver fat content
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 63
1
Related topics
6
Evidence pairs
177
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
Weight Loss
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Pemvidutide reduced liver fat content by up to 76.4%.
- Body weight decreased by 6.2% across all pemvidutide doses.
- Statistical significance was noted with p-values of 0.001.
A quién se aplica
- Adults diagnosed with metabolic dysfunction-associated steatotic liver disease.
- Individuals seeking treatment options for liver fat reduction.
Tener en Cuenta
- Results may not be applicable to populations outside the study sample.
- Effects observed in a controlled setting may differ in real-world scenarios.
- Further studies are needed to assess long-term safety and efficacy.
Entre Líneas
- Limited sample size may affect generalizability.
- Short duration of 24 weeks may not capture long-term effects.
- No significant difference in body weight reduction compared to placebo.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Pemvidutide 1.2 mg and Body Weight, Pemvidutide 1.2 mg and Liver fat content.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Pemvidutide 1.2 mg → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceMedications
Pemvidutide 1.2 mg → Liver fat content
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Liver fat content Evidence Hub
All studies measuring Liver fat content
1 studies
outcome_hubMeasures Liver fat content as a key outcome.
Pemvidutide 1.2 mg Evidence Hub
All studies on Pemvidutide 1.2 mg
1 studies
intervention_hubContributes to Pemvidutide 1.2 mg evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Pemvidutide 1.2 mg and Body weight
Intervention: Pemvidutide 1.2 mgOutcome: Body weight
1 results
All studies on Pemvidutide 1.2 mg and Liver fat content
Intervention: Pemvidutide 1.2 mgOutcome: Liver fat content
1 results
All studies on Pemvidutide 1.2 mg
Intervention: Pemvidutide 1.2 mg
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
All studies measuring Liver fat content
Outcome: Liver fat content
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Pemvidutide 1.2 mg affect body weight?
Emerging Evidence
Pemvidutide 1.2 mg appears to improve Body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Pemvidutide 1.2 mg improve liver fat content?
Emerging Evidence
Pemvidutide 1.2 mg appears to improve Liver fat content.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Liver fat content
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Pemvidutide 1.8 mg affect body weight?
Emerging Evidence
Pemvidutide 1.8 mg appears to improve Body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Pemvidutide 1.8 mg improve liver fat content?
Emerging Evidence
Pemvidutide 1.8 mg appears to improve Liver fat content.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Liver fat content
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
5:2 Diet Improves Glycemic Control in Type 2 DiabetesHealthy Nordic Diet Improves Liver Fat in Type 2 DiabetesDietary interventions improve glycemic control in pre-diabetic patientsMK-3655 shows modest reduction in liver fat for pre-cirrhotic MASHMetabolomics score improves metabolic profiling in diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.